Abstract
Background
We evaluated the usefulness of bisphosphonate (BIS) monotherapy, the safety of rapid infusion of BIS and the efficacy of BIS-sequential therapy for bone metastases from breast cancer.
Patients and Methods
Twenty-nine patients with bone metastasis or invasion were treated with BIS monotherapy. Each BIS (pamidronate 30 mg, alendronate 10 mg, or incadronate 10 mg) was infused over 30 minutes every two weeks a median of 12 times.
Results
With BIS therapy, five patients (17%) showed partial response of the bone lesions, and eighteen patients (64%) had pain relief. Of the nine patients treated with BIS-sequential therapy, one (11%) showed a partial response of the bone metastases, three (33%) had pain relief, and one (11%) showed a decrease in the serum tumor marker level.
Conclusion
BIS therapy is effective against bone metastases from breast cancer, and rapid infusion of BIS is both safe and convenient for patients. BIS-sequential therapy can be a unique therapeutic option in some cases.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
Abbreviations
- BIS:
-
bisphosphonate
References
Liberman UA, Weiss SR, Broil J,et al: Effect of alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis.N Engl J Med 333:1437–1443, 1995.
Body JJ, Pot M, Borkowski A,et al: Dose/response study of aminohydroxypropylidene bisphosphonate in tumor-associated hypercalcemia.Am J Med 82:957–963, 1987.
Hortobagyi GN, Theriault RL, Porter L,et al: Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases.N Engl J Med 335:1785–1791, 1996.
Theriault RL, Lipton A, Hortobagyi GN,et al: Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: A randomized, placebo-controlled trial.J Clin Oncol 17:846–854, 1999.
Wallach S: The role of calcitonin treatment in postmenopausal osteoporosis.Orthopedic Rev 21:1034–1131, 1992.
Takahashi S, Goldring S, Katz M,et al:. Downregulation of calcitonin receptor mRNA expression by calcitonin during human osteoclast-like cell differentiation.J Clin Invest 95:167–171, 1995.
The Japanese Breast Cancer Society: General rules for clinical and pathological recording of breast cancer, 13th ed, Kanehara Co., Tokyo, pp57–68. 1998.
Coleman RE, Woll PJ, Miles M,et al: Treatment of bone metastases from breast cancer with (3-amino-1-hydroxypropylidene) -1, 1-bisphosphonate (APD).Br J Cancer 58:621–625, 1988.
Bounameaux HM, Schifferli J, Montani JP,et al: Renal failure associated with intravenous diphosphonates Getter).Lancet 1:471, 1983.
Fitton A, McTavish D: Pamidronate: A review of its pharmacological properties and therapeutic efficacy in resorptive bone disease.Drugs 41:289–318, 1991.
Leyvraz S, Hess U, Flesch G,et al:. Pharmacokinetics of pamidronate in patients with bone metastases.J Natl Cancer Inst 84:788–792, 1992.
Radzwill AJ, Thürlimann B, Jungi WF: Improvement of palliation in patients with osteolytic bone disease and unsatisfactory pain control after pretreatment with disodium pamidronate: An intra-patient dose escalation study.Onkologie 16:174–177, 1993.
Author information
Authors and Affiliations
About this article
Cite this article
Oura, S., Tanino, H., Yoshimasu, T. et al. Bisphosphonate therapy for bone metastases from Breast Cancer: Clinical results and a new therapeutic approach. Breast Cancer 7, 307–310 (2000). https://doi.org/10.1007/BF02966395
Issue Date:
DOI: https://doi.org/10.1007/BF02966395